Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2CNS 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 6Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Diseases 1Uterine Cervical Diseases 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Recurrent Uterine Corpus Sarcoma 1Prostatic Neoplasms 1Hypertension 1Glioblastoma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × pazopanib × Gynecologic × Clear all
NCT01610206 2021-02-25

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

University of Virginia

Phase 2 Completed
148 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT00430781 2015-05-08

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

GlaxoSmithKline

Phase 2 Completed
228 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡